ENITEC Tweet European Network of Individual Treatment in Endometrial Cancer ENITEC is a pan-European academic Network for Gynaecological Oncological Translational Researchers who gather together to share their expertise in uterine cancer research, with a particular focus on integration of molecular studies to improve and individualize patient care. The ultimate goal of the Network is to improve and individualize treatment of women with uterine cancers by integrating the best science in state of the art for clinical care, and enabling every patient to access benefits from translational research. Activities Annual Meeting The 2016 annual meeting will be held on 9th-10th of June in Freiburg, Germany. Collaborative Studies The Network will discuss updates about the already ongoing collaborative studies and evaluate the proposal of new projects. PublicationsThe project entitled “Therapeutic targets in uterine sarcomas: an IHC study”, coordinated by Frederic Amant (KULeuven, BE, ENITEC Co-Chair) and involving from the beginning 13 centres inside ENITEC has been finalized in 2015 and will be published in 2016. The validation study aimed to unravel the prognostic significance of L1CAM in endometrioid (EEC) and non-endometrioid endometrial cancer (NEEC), coordinated by Johanna Pijnenborg (Tilborg, NL) and Louis Van Der Putten (Nijmegen, NL) and involving several centres inside ENITEC, has been finalized in 2015 and will be published in 2016. DatabasesDevelopment of the RUCaRe (Rare Uterine Cancer Registry) initiative. Clinical StudiesThe ENITEC Network provides its members the opportunity to join a TAKEDA sponsored PHASE-II clinical trial commencing in February 2016. This joint initiative of ENITEC-EUTROC-TAKEDA, involves treatment of women with Advanced, Recurrent, or persistent Endometrial Cancer with MLN0128 (A dual TORC 1/2 inhibitor), MLN0128+MLN117 (a PI3Kα Inhibitor), Weekly Paclitaxel and a combination of weekly Paclitaxel and MLN0128 in 4 patient arms.260 patients from approximately 60 centres across North America, Europe and Asia Pacific will be randomized into the study. Tissue material (baseline and follow up biopsies) will be used to generate research material (frozen and fixed tissue) available from the patient arms. This material will be available to EUTROC-ENITEC investigators from TAKEDA to investigate important translational science questions. Join or renew today Directly to: ESGO‘s Upcoming Conference eAcademy Premium Collection ESGO‘s Journal latest articles myESGO ESGO Newsletter Get notified on all news and activities right in your mailbox. Upcoming events Workshop MOLECULAR TUMORBIOLOGY April 7-8, 2017, Leuven, Belgium Read More Congress ESGO 20th CONGRESSNov 4-7, 2017, Vienna, Austria Read More European Society of Gynaecological Oncology The European Society of Gynaecological Oncology (ESGO) is the leading European organization with more than 3000 professionals involved in treatment, care and research of gynaecologic cancers. Contact us Explore ESGO eAcademy Journal Attend ESGO Congress SoA Conference Meetings Calendar Network Networks ENYGO ENGOT Join Become a Member myESGO Members Directory News Updates Get notified on all of ESGO’s news and activities.